The phase III ENDEAR study utilizing nusinersen, an antisense oligonucleotide that increases the proportion of full-length SMN protein, found that symptomatic Type I SMA patients were more likely to exhibit a motor-milestone response and had a prolonged time to death or needing permanent ventilation [21]. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.